Amneal Pharmaceuticals, Inc. AMRX Unrealized Gain (Loss), Foreign Currency Transaction, before Tax
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossUnrealized.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s unrealized gain (loss), foreign currency transaction, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s unrealized gain (loss), foreign currency transaction, before tax?
- Amneal Pharmaceuticals, Inc. (AMRX) reported unrealized gain (loss), foreign currency transaction, before tax of -$8.22M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s unrealized gain (loss), foreign currency transaction, before tax changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s unrealized gain (loss), foreign currency transaction, before tax decreased by 328.4% year-over-year, from $3.6M to -$8.22M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s unrealized gain (loss), foreign currency transaction, before tax?
- Over 2 years (2021 to 2024), Amneal Pharmaceuticals, Inc.'s unrealized gain (loss), foreign currency transaction, before tax has grown at a 541.0% compound annual growth rate (CAGR), from -$175K to -$7.19M.
- What does unrealized gain (loss), foreign currency transaction, before tax mean?
- This captures the non-cash impact of exchange rate fluctuations on monetary assets and liabilities denominated in foreign currencies. It highlights the company's exposure to international market volatility before tax effects are applied.